Meet the Team
Chief Executive Officer & Co-Founder
Asaf Zviran
Experienced entrepreneur, scientist, and executive with over 20 years of product development, business development, and team management in defense and biotech. Previously, the Co-Founder, CEO & CSO of C2i Genomics, taking the company from a research concept to a global commercial leader.
​
Chief Science Officer & Co-Founder
Orly Alter
Inventor of the “Eigengene.” USTAR associate professor at the Scientific Computing and Imaging Institute and the Huntsman Cancer Institute at the University of Utah, and a member of the scientific advisory board of the NCI-DOE Cancer Moonshot collaboration on predictive oncology.
​
Chief Technology Officer & Co-Founder
Daniel Shabtai
Technology leader with 11 years of experience from Facebook/Meta in leading engineering roles. Built and managed high-performing engineering organizations of over 300 people across multiple locations. Utilized AI/ML, scalable systems design, and data privacy concepts for products at large scale with billions of users.
Fractional CBO
Mark Oldroyd
Biotech business leader with over 30 years of experience in executive roles. Previously led multiple commercial and business development teams at Foundation Medicine, Tempus AI, C2i Genomics, and Culmination Bio. Serves on the board of directors at multiple startup companies.
​​​
Fractional VP Finance
Jason Friske
20 years of accounting and finance experience and 10 years of startup experience in the NYC area that includes private and public companies based in the US and Israel. Most recently helped to complete the due diligence, sale and transition of C2i Genomics to Veracyte.
​
​
Non-Executive Board Director
David Sidransky
Dr. Sidransky is a renowned oncologist, research scientist, and serial entrepreneur, profiled by TIME magazine in 2001 as one of America's best in science and medicine. A leading expert in oncology and precision medicine, Dr. Sidransky is widely respected in the biopharmaceutical industry.
​